Related Experiment Video
Updated: Dec 26, 2025

Tilt Testing with Combined Lower Body Negative Pressure: a "Gold Standard" for Measuring Orthostatic Tolerance
Published on: March 21, 2013
Classical and Delayed Orthostatic Hypotension in Patients With Unexplained Syncope and Severe Orthostatic Intolerance
Parisa Torabi1,2, Fabrizio Ricci1,3, Viktor Hamrefors1,4
1Department of Clinical Sciences, Faculty of Medicine, Clinical Research Center, Lund University, Malmö, Sweden.
Insights
Classical orthostatic hypotension (cOH) patients are older and exhibit distinct neuroendocrine profiles compared to delayed OH (dOH). This study differentiates cOH and dOH, revealing key clinical and hormonal differences in cardiovascular autonomic failure.
Area of Science:
- Cardiology
- Neurology
- Endocrinology
Background:
- Orthostatic hypotension (OH) is a significant indicator of cardiovascular autonomic failure, causing orthostatic intolerance and syncope.
- OH is classified into classical (cOH) and delayed (dOH) forms, with limited understanding of their distinct characteristics.
- This study provides a comprehensive clinical and neuroendocrine evaluation of OH subtypes.
Purpose of the Study:
- To systematically characterize and compare classical OH (cOH) and delayed OH (dOH) in patients presenting with unexplained syncope.
- To investigate the differences in clinical presentation, hemodynamic responses, and neuroendocrine profiles between cOH and dOH.
- To elucidate the pathophysiology underlying these two variants of orthostatic hypotension.
Main Methods:
- Analysis of 2,167 patients with unexplained syncope and orthostatic intolerance undergoing cardiovascular autonomic testing, including head-up tilt (HUT).
- Identification and detailed comparison of clinical history, demographics, and hemodynamic variables between cOH and dOH cohorts.
- Measurement of plasma levels of key neuroendocrine markers (epinephrine, norepinephrine, CT-proAVP, etc.) in supine and HUT positions.
Main Results:
- 27% of the cohort (248 cOH, 336 dOH) were diagnosed with OH.
- cOH patients were older, more frequently male, and had higher supine blood pressure, lower eGFR, and more comorbidities like Parkinson's disease and arrhythmias.
- Neuroendocrine analysis revealed higher supine and HUT CT-proAVP in cOH, greater HUT epinephrine increase in cOH, and a more pronounced norepinephrine increase in dOH.
Conclusions:
- Classical OH is characterized by older age, supine hypertension, specific comorbidities, and distinct neuroendocrine responses involving vasopressin and epinephrine.
- The findings highlight significant differences between cOH and dOH, suggesting distinct pathophysiological mechanisms.
- Understanding these differences is crucial for accurate diagnosis and tailored management of orthostatic hypotension.
Abstract:
Background: Orthostatic hypotension (OH) is a major sign of cardiovascular autonomic failure leading to orthostatic intolerance and syncope. Orthostatic hypotension is traditionally divided into classical OH (cOH) and delayed OH (dOH), but the differences between the two variants are not well-studied. We performed a systematic clinical and neuroendocrine characterization of OH patients in a tertiary syncope unit. Methods: Among 2,167 consecutive patients (1,316 women, 60.7%; age, 52.6 ± 21.0 years) evaluated for unexplained syncope and severe orthostatic intolerance with standardized cardiovascular autonomic tests including head-up tilt (HUT), we identified those with a definitive diagnosis of cOH and dOH. We analyzed patients' history, clinical characteristics, hemodynamic variables, and plasma levels of epinephrine, norepinephrine, C-terminal-pro-arginine-vasopressin (CT-proAVP), C-terminal-endothelin-1, mid-regional-fragment of pro-atrial-natriuretic-peptide and pro-adrenomedullin in the supine position and at 3-min HUT. Results: We identified 248 cOH and 336 dOH patients (27% of the entire cohort); 111 cOH and 152 dOH had blood samples collected in the supine position and at 3-min HUT. Compared with dOH, cOH patients were older (68 vs. 60 years, p < 0.001), more often male (56.9 vs. 39.6%, p < 0.001), had higher systolic blood pressure (141 vs. 137 mmHg, p = 0.05), had lower estimated glomerular filtration rate (73 vs. 80 ml/min/1.73 m2, p = 0.003), more often pathologic Valsalva maneuver (86 vs. 49 patients, p < 0.001), pacemaker-treated arrhythmia (5 vs. 2%, p = 0.04), Parkinson's disease (5 vs. 1%, p = 0.008) and reported less palpitations before syncope (16 vs. 29%, p = 0.001). Supine and standing levels of CT-proAVP were higher in cOH (p = 0.022 and p < 0.001, respectively), whereas standing norepinephrine was higher in dOH (p = 0.001). After 3-min HUT, increases in epinephrine (p < 0.001) and CT-proAVP (p = 0.001) were greater in cOH, whereas norepinephrine increased more in dOH (p = 0.045). Conclusions: One-quarter of patients with unexplained syncope and severe orthostatic intolerance present orthostatic hypotension. Classical OH patients are older, more often have supine hypertension, pathologic Valsalva maneuver, Parkinson's disease, pacemaker-treated arrhythmia, and lower glomerular filtration rate. Classical OH is associated with increased vasopressin and epinephrine during HUT, but blunted increase in norepinephrine.
Related Concept Videos
Alterations in Blood Pressure
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
Disorders of the Autonomic Nervous System
Raynaud's disease, also known as Raynaud's...
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Heart Failure Drugs: β-Blockers
Measurement of Blood Pressure
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

